Goldman Sachs has upgraded BioNTech SE (NASDAQ:BNTX), citing the company’s BNT327, an immuno-oncology asset in clinical ...

Fintel reports that on November 8, 2024, Goldman Sachs upgraded their outlook for BioNTech SE - Depositary Receipt () ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $127.53, ...

In a report released yesterday, Chris Shibutani from Goldman Sachs upgraded BioNTech SE (BNTX – Research Report) to a Buy, with a price ...

Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...

Robert Burns, an analyst from H.C. Wainwright, reiterated the Buy rating on BioNTech SE (BNTX – Research Report). The associated price ...

BioNTech SE (BNTX) reports strong revenue growth and pipeline progress, while navigating financial and legal hurdles.

Operator Welcome to BioNTech's third quarter 2024 earnings call. I would like to hand the call over to Michael Horowicz ...

Driven by the early approval of its updated COVID-19 vaccine, BioNTech far exceeded analysts’ expectations in the third ...

On Monday, BioNTech SE (NASDAQ:BNTX) reported third-quarter revenues of 1.244 billion euros (or $1.36 billion), up from 895.3 ...

Despite the performance, the company expects to be at the lower end of its revenue guidance window for the year of between €2 ...

BioNTech reported better-than-expected quarterly results helped by solid sales of its variant-adapted Covid-19 vaccines.